Pharmacological inhibition of HSP90 and ras activity as a new strategy in the treatment of HNSCC

Journal of Cellular Physiology

Volumn 228, Issue 1, 2013, Pages 130-141

  Misso, Gabriella ^a   Giuberti, Gaia ^a   Lombardi, Angela ^a   Grimaldi, Anna ^a   Ricciardiello, Filippo ^b   Giordano, Antonio ^c,d   Tagliaferri, Pierosandro ^e   Abbruzzese, Alberto ^a   Caraglia, Michele ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c Temple University   (United States)

^d UNIVERSITY OF SIENA   (Italy)

^e Medical Oncology Unit   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; TIPIFARNIB;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN KB; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENTIATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEP 2 CELL; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOQUINONES; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; QUINOLONES; RAS PROTEINS; SIGNAL TRANSDUCTION; TAXOIDS;

EID: 84867186771     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24112     Document Type: Article

References (40)

1. Blagg BS, Kerr TD. 2006. Hsp90 inhibitors: Small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation. Med Res Rev 26: 310-338.
2. Budillon A, Bruzzese F, Di Gennaro E, Caraglia M. 2005. Multiple-target drugs: Inhibitors of heat shock protein 90 and of histone deacetylase. Curr Drug 6: 337-351.
3. Caraglia M, Giuberti G, Marra M, Di Gennaro E, Facchini G, Caponigro F, Iaffaioli R, Budillon A, Abbruzzese A. 2005. Docetaxel induces p53-dependent apoptosis and synergizes with farnesyl transferase inhibitor r115777 in human epithelial cancer cells. Front Biosci 10: 2566-2575.
4. Caraglia M, Marra M, Leonetti C, Meo G, D'Alessandro AM, Baldi A, Santini D, Tonini G, Bertieri R, Zupi G, Budillon A, Abbruzzese A. 2007. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. J Cell Physiol 211: 533-543.
5. Chen S, Sullivan WP, Toft DO, Smith DF. 1998. Differential interactions of p23 and the TPR-containing proteins Hop, Cyp40, FKBP52 and FKBP51 with Hsp90 mutants. Cell Stress Chaperon 3: 118-129.
6. Crown J, O'Leary M. 2000. The taxanes: An update. Lancet 355: 1176-1178.
7. Dasgupta S, Dash R, Das SK, Sarkar D, Fisher PB. 2012. Emerging strategies for the early detection and prevention of head and neck squamous cell cancer. J Cell Physiol 227: 467-473.
8. Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao AS. 2010. Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol 29: 2-15.
9. Eloa MA, Kaarnirantab K. 2005. Hsp90 inhibitor geldanamycin increases hsp70 mRNA stabilisation but fails to activate HSF1 in cells exposed to hydrostatic pressure. Biochim Biophys Acta 1743: 115-119.
10. End DW. 1999. Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway. Invest New Drugs 17: 241-258.
11. Franceschi S, Barzan L, Talamini R. 1997. Screening for cancer of the head and neck: If not now, when? Oral Oncol 33: 313-316.
12. Fukuyo Y, Hunt CR, Horikoshi N. 2010. Geldanamycin and its anti-cancer activities. Cancer Lett 290: 24-35.
13. Haldar S, Basu A, Croce CM. 1997. Bcl2 is the guardian of microtubule integrity. Cancer Res 57: 229-233.
14. Hammarstedt L, Lindquist D, Dahlstrand H, Romanitan M, Dahlgren LO, Joneberg J, Creson N, Lindholm J, Ye W, Dalianis T, Munck-Wikland E. 2006. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer 119: 2620-2623.
15. Harousseau JL, Martinelli G, Jedrzejczak WW, Brandwein JM, Bordessoule D, Masszi T, Ossenkoppele GJ, Alexeeva JA, Beutel G, Maertens J, Vidriales MB, Dombret H, Thomas X, Burnett AK, Robak T, Khuageva NK, Golenkov AK, Tothova E, Mollgard L, Park YC, Bessems A, De Porre P, Howes AJ; FIGHT-AML-301 Investigators. 2009. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood 114: 1166-1173.
16. Hashiramoto A, Murata M, Kawazoe T, Yoshida K, Akiyama C, Shiozawa K, Shiozawa S. 2012. Heat shock protein 90 maintains the tumour-like character of rheumatoid synovial cells by stabilizing integrin-linked kinase, extracellular signal-regulated kinase and protein kinase B. Rheumatology (Oxford). 50: 852-861.
17. Huang CE, Lu CH, Chen PT, Chan CH, Chen WC, Wang WH, Wu JY, Kuan FC, Lee KD, Chen CC. 2012. Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer. J Clin Pharm Ther 37: 342-347.
18. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. 2008. Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
19. Kelland LR, Smith V, Valenti M, Patterson L, Clarke PA, Detre S, End D, Howes AJ, Dowsett M, Workman P, Johnston SR. 2001. Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin Cancer Res 7: 3544-3550.
20. Kuo ML, Chuang SE, Lin MT, Yang SY. 2001. The involvement of PI 3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Hep3B cells by interleukin-6. Oncogene 20: 677-685.
21. Liu B, Fang M, Lu Y, Mendelsohn J, Fan Z. 2001. Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by antiepidermal growth factor receptor monoclonal antibody. Oncogene 20: 1913-1922.
22. McCubrey JA, Steelman LS, Kempf CR, Chappell WH, Abrams SL, Stivala F, Malaponte G, Nicoletti F, Libra M, Bäsecke J, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Cocco L, Martelli AM. 2011. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol 226: 2762-2781.
23. Meyer P, Prodromou C, Liao C, Hu B, Roe SM, Vaughan CK, Vlasic I, Panaretou B, Piper PW, Pearl LH. 2004. Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery. EMBO J 23: 1402-1410.
24. Mitsui H, Takuwa N, Maruyama T, Maekawa H, Hirayama M, Sawatari T, Hashimoto N, Takuwa Y, Kimura S. 2001. The MEK1-ERK map kinase pathway and the PI 3-kinase-Akt pathway independently mediate anti-apoptotic signals in HepG2 liver cancer cells. Int J Cancer 92: 55-62.
25. Orr AG, Verdier-Pinard P, McDaid H, Horwitz SB. 2003. Mechanisms of Taxol resistance related to microtubules. Oncogene 22: 7280-7295.
26. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J. 1997. Cancer incidence in five continents Vol. VII. Lyon: IARC Scientific Publications.
27. Powers MV, Workman P. 2006. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 13: S125-S135.
28. Price KA, Cohen EE. 2012. Current treatment options for metastatic head and neck cancer. Curr Treat Options Oncol 13: 35-46.
29. Richter K, Buchner J. 2001. Hsp90: Chaperoning signal transduction. J Cell Physiol 188: 281-290.
30. Sebti SM, Hamilton AD. 2000. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: Important mechanistic and bench to bedside issues. Exp Opin Invest Drugs 9: 2767-2782.
31. Selleri C, Maciejewski JP, Montuori N, Ricci P, Visconte V, Serio B, Luciano L, Rotoli B. 2003. Involvement of nitric oxide in farnesyltransferase inhibitor-mediated apoptosis in chronic myeloid leukemia cells. Blood 102: 1490-1498.
32. Shiboski CH, Schmidt BL, Jordan RC. 2005. Tongue and tonsil carcinoma: Increasing trends in the U.S. population ages20-44 years. Cancer 103: 1843-1849.
33. Shu CW, Cheng NL, Chang WM, Tseng TL, Lai YK. 2005. Transactivation of hsp70-1/2 in geldanamycintreated human non-small cell lung cancer H460 cells: Involvement of intracellular calcium and protein kinase C. J Cell Biochem 94: 1199-1209.
34. Somani N, Goyal S, Pasricha R, Khuteta N, Agarwal P, Garg AK, Singhal H. 2011. Sequential therapy (triple drug-based induction chemotherapy followed by concurrent chemoradiotherapy) in locally advanced inoperable head and neck cancer patients - Single institute experience. Indian J Med Paediatr Oncol 32: 86-91.
35. von Gise A, Lorenz P, Wellbrock C, Hemmings B, Berberich-Siebelt F, Rapp UR, Troppmair J. 2001. Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals. Mol Cell Biol 21: 2324-2336.
36. Wang LG, Liu XM, Kreis W, Budman DR. 1999. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: A review. Cancer Chemoter Pharmacol 44: 355-361.
37. Whelan JT, Hollis SE, Cha DS, Asch AS, Lee MH. 2012. Post-transcriptional regulation of the Ras-ERK/MAPK signaling pathway. J Cell Physiol 227: 1235-1241.
38. Xu W, Yuan X, Jung YJ, Yang Y, Basso A, Rosen N, Chung EJ, Trepel J, Neckers L. 2003. The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells. Cancer Res 63: 7777-7784.
39. Zhang H, Burrows F. 2004. Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 82: 488-499.
40. Zhou H, Li XM, Meinkoth J, Pittman RN. 2000. Akt regulates cell survival and apoptosis at a postmitochondrial level. Cell Biol 151: 483-494.